Phylos Inc.'s combinatorial biology platform technology has its roots in basic molecular biology, but the company plans to extend its technology to fields such as proteomics and directed protein evolution to develop protein-based therapeutic and diagnostic products.

The company's platform is based on its PROfusion technology, exclusively licensed from Massachusetts General Hospital. PROfusion begins with a library of up to 1014 synthetic mRNA molecules fused to the protein that each RNA encodes.